Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care

被引:7
作者
Burgers, L. E. [1 ]
van der Pol, J. A. [1 ]
Huizinga, T. W. J. [1 ]
Allaart, C. F. [1 ]
van der Helm-van Mil, A. H. M. [1 ,2 ]
机构
[1] Leiden Univ, Dept Rheumatol, Med Ctr, C-01-046,POB 9600, NL-2300 RC Leiden, Netherlands
[2] Erasmus MC, Dept Rheumatol, Rotterdam, Netherlands
基金
欧洲研究理事会;
关键词
Rheumatoid arthritis; Epidemiology; Outcome measures; DMARDs; Study design; DRUG-FREE REMISSION; EARLY RHEUMATOID-ARTHRITIS; OUTCOMES; RECOMMENDATIONS; ETANERCEPT;
D O I
10.1186/s13075-019-1893-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA).MethodsTwo hundred seventy-nine RA patients (median follow-up 7.8years) were studied. Of these, 155 patients participated in a disease activity score (DAS) <1.6 steered trial aimed at DMARD-free remission. Initial treatment comprised methotrexate with high-dose prednisone (60mg/day) and a possibility to start biologicals after 4months. In the same period and hospital, 124 patients were treated according to routine care, comprising DAS <2.4 steered treatment. Percentages of DMARD-free remission (absence of synovitis for 1year after DMARD cessation), late flares (recurrence of clinical synovitis 1year after DMARD cessation), and DMARD-free sustained remission (DMARD-free remission sustained during complete follow-up) were compared between both treatment strategies.ResultsPatients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard ratio (HR) 1.4, 95%CI 0.9-2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4-17). Intensive treatment was associated with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6-8.3). Subsequently, there was no difference in DMARD-free sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9-11).ConclusionsIntensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs further investigation.
引用
收藏
页数:10
相关论文
共 24 条
  • [1] Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms
    Ajeganova, S.
    van Steenbergen, H. W.
    van Nies, J. A. B.
    Burgers, L. E.
    Huizinga, T. W. J.
    van der Helm-van Mil, A. H. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 867 - 873
  • [2] Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study
    Akdemir, Gulsah
    Heimans, Lotte
    Bergstra, Sytske Anne
    Goekoop, Robbert J.
    van Oosterhout, Maikel
    van Groenendael, Johannes H. L. M.
    Peeters, Andre J.
    Steup-Beekman, Gerda M.
    Lard, Leroy R.
    de Sonnaville, Peter B. J.
    Grillet, Bernard A. M.
    Huizinga, Tom W. J.
    Allaart, Cornelia F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (01) : 111 - 118
  • [3] Understanding the window of opportunity concept in early rheumatoid arthritis
    Boers, M
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (07): : 1771 - 1774
  • [4] Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic?
    de Rooy, Diederik P. C.
    van der Linden, Michael P. M.
    Knevel, Rachel
    Huizinga, Tom W. J.
    van der Helm-van Mil, Annette H. M.
    [J]. RHEUMATOLOGY, 2011, 50 (01) : 93 - 100
  • [5] EARLY RHEUMATOID-ARTHRITIS - TIME TO AIM FOR REMISSION
    EMERY, P
    SALMON, M
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (12) : 944 - 947
  • [6] Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
    Emery, Paul
    Burmester, Gerd R.
    Bykerk, Vivian P.
    Combe, Bernard G.
    Furst, Daniel E.
    Barre, Emilie
    Karyekar, Chetan S.
    Wong, Dennis A.
    Huizinga, Tom W. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (01) : 19 - 26
  • [7] Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
    Emery, Paul
    Hammoudeh, Mohammed
    FitzGerald, Oliver
    Combe, Bernard
    Martin-Mola, Emilio
    Buch, Maya H.
    Krogulec, Marek
    Williams, Theresa
    Gaylord, Stefanie
    Pedersen, Ronald
    Bukowski, Jack
    Vlahos, Bonnie
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1781 - 1792
  • [8] American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
    Felson, David T.
    Smolen, Josef S.
    Wells, George
    Zhang, Bin
    van Tuyl, Lilian H. D.
    Funovits, Julia
    Aletaha, Daniel
    Allaart, Cornelia F.
    Bathon, Joan
    Bombardieri, Stefano
    Brooks, Peter
    Brown, Andrew
    Matucci-Cerinic, Marco
    Choi, Hyon
    Combe, Bernard
    de Wit, Maarten
    Dougados, Maxime
    Emery, Paul
    Furst, Daniel
    Gomez-Reino, Juan
    Hawker, Gillian
    Keystone, Edward
    Khanna, Dinesh
    Kirwan, John
    Kvien, Tore K.
    Landewe, Robert
    Listing, Joachim
    Michaud, Kaleb
    Martin-Mola, Emilio
    Montie, Pamela
    Pincus, Theodore
    Richards, Pamela
    Siegel, Jeffrey N.
    Simon, Lee S.
    Sokka, Tuulikki
    Strand, Vibeke
    Tugwell, Peter
    Tyndall, Alan
    van der Heijde, Desiree
    Verstappen, Suzan
    White, Barbara
    Wolfe, Frederick
    Zink, Angela
    Boers, Maarten
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (03): : 573 - 586
  • [9] Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)
    Heimans, Lotte
    Akdemir, Gulsah
    Wevers-de Boer, Kirsten V. C.
    Goekoop-Ruiterman, Yvonne P.
    Molenaar, Esmeralda T.
    van Groenendael, Johannes H. L. M.
    Peeters, Andreas J.
    Steup-Beekman, Gerda M.
    Lard, Leroy R.
    de Sonnaville, Peter B. J.
    Grillet, Bernard A. M.
    Huizinga, Tom W. J.
    Allaart, Cornelia F.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [10] Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
    Huizinga, T. W. J.
    Conaghan, Philip G.
    Martin-Mola, Emilio
    Schett, Georg
    Amital, Howard
    Xavier, Ricardo M.
    Troum, Orrin
    Aassi, Maher
    Bernasconi, Corrado
    Dougados, Maxime
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (01) : 35 - 43